Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Can circulating microRNAs predict colorectal cancer? Results from a nested case-control study of pre-diagnostic serum samples from two prospective biobanks.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Colorectal Neoplasms*/genetics ; Colorectal Neoplasms*/blood ; Colorectal Neoplasms*/diagnosis ; Colorectal Neoplasms*/pathology ; Biomarkers, Tumor*/blood ; Biomarkers, Tumor*/genetics ; Circulating MicroRNA*/blood ; Circulating MicroRNA*/genetics ; MicroRNAs*/blood ; MicroRNAs*/genetics; Humans ; Female ; Male ; Case-Control Studies ; Prospective Studies ; Middle Aged ; Biological Specimen Banks ; Aged ; Adult ; Gene Expression Regulation, Neoplastic
    • Abstract:
      Competing Interests: Declarations. Ethics approval and consent to participate: The study was approved by “REK midt (REC central)”, Norwegian University of Science and Technology, Trondheim Norway, ( https://rekportalen.no/#omrek/REK ) with reference 2016/534. All participants provided informed consent as participants in the health surveys. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.
      Background: This study aimed to investigate the potential of circulating small RNAs (sRNAs) as predictive biomarkers for future colorectal cancer (CRC). The study analyzed serum samples from pre-diagnostic CRC patients in two prospective biobanks.
      Methods: Serum samples from 142 pre-diagnostic CRC patients, from the Finnish Maternity Cohort (FMC) and The HUNT Study (HUNT2), were subjected to small RNA sequencing. The study compared sRNA expression in CRC cases with controls, considering diverse sRNA classes.
      Results: Analysis revealed diverse miRNA expression patterns with notable variations in future metastatic cases. Specifically, miR-223-3p and miR-21-5p showed significant up-regulation in future metastatic cases in the FMC cohort. Consistent changes were observed across cohorts, with miR-584-5p, miR-30c-5p, miR-146a-5p, miR-10a-5p, and miR-1306-5p showing up-regulation in future metastatic cases.
      Conclusions: The study identified potential serum miRNA biomarkers associated with metastatic CRC, though statistical significance varied. These findings contribute to the understanding of miRNA profiles in pre-diagnostic CRC patients, emphasizing the need for further exploration of non-invasive biomarkers in large prospective studies.
      (© 2025. The Author(s).)
    • References:
      Cancer. 1974 Sep;34(3):suppl:845-9. (PMID: 4851945)
      Am J Gastroenterol. 2020 May;115(5):662-670. (PMID: 31972617)
      Clin Radiol. 1984 Nov;35(6):425-31. (PMID: 6499378)
      CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
      Nucleic Acids Res. 2015 Apr 20;43(7):e47. (PMID: 25605792)
      World J Gastroenterol. 2013 Sep 14;19(34):5615-21. (PMID: 24039353)
      Am J Gastroenterol. 2006 Feb;101(2):380-4. (PMID: 16454847)
      Int J Epidemiol. 2023 Feb 8;52(1):e80-e91. (PMID: 35578897)
      Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8. (PMID: 18663219)
      PLoS One. 2022 Aug 31;17(8):e0268958. (PMID: 36044434)
      JAMA Oncol. 2017 Feb 01;3(2):211-219. (PMID: 27787550)
      Nat Rev Clin Oncol. 2014 Mar;11(3):145-56. (PMID: 24492836)
      Cancer Med. 2017 Dec;6(12):3060-3064. (PMID: 29071810)
      JAMA Netw Open. 2024 Feb 5;7(2):e240516. (PMID: 38411959)
      Oncotarget. 2017 Sep 30;8(52):90077-90089. (PMID: 29163812)
      Surg Oncol Clin N Am. 1996 Jul;5(3):513-30. (PMID: 8829316)
      Nucleic Acids Res. 2008 Jan;36(Database issue):D154-8. (PMID: 17991681)
      Oncogene. 2008 Apr 3;27(15):2128-36. (PMID: 17968323)
      J Postgrad Med. 2016 Apr-Jun;62(2):91-5. (PMID: 27089107)
      Br J Cancer. 2023 Feb;128(4):656-664. (PMID: 36446884)
      J Natl Cancer Inst. 2013 Jun 19;105(12):849-59. (PMID: 23704278)
      PLoS One. 2011;6(11):e27008. (PMID: 22073238)
      Nucleic Acids Res. 2021 Jan 8;49(D1):D212-D220. (PMID: 33106848)
      RNA Biol. 2011 May-Jun;8(3):506-16. (PMID: 21558792)
      Mol Oncol. 2023 Feb;17(2):312-327. (PMID: 36337027)
      Cancers (Basel). 2019 Oct 12;11(10):. (PMID: 31614785)
      Signal Transduct Target Ther. 2016 Jan 28;1:15004. (PMID: 29263891)
      Clin Colorectal Cancer. 2024 Mar;23(1):22-34.e2. (PMID: 37980216)
      Br J Cancer. 2013 Apr 30;108(8):1712-9. (PMID: 23558896)
      Cancer J. 2012 May-Jun;18(3):244-52. (PMID: 22647361)
      Ann Oncol. 2016 Oct;27(10):1879-86. (PMID: 27502702)
      Oncotarget. 2015 Jan 30;6(3):1740-9. (PMID: 25638153)
      Exp Ther Med. 2020 Mar;19(3):2059-2066. (PMID: 32104266)
    • Contributed Indexing:
      Keywords: Biomarkers; Colorectal Neoplasms; Diagnosis; MicroRNAs; Serum
    • Accession Number:
      0 (Biomarkers, Tumor)
      0 (Circulating MicroRNA)
      0 (MicroRNAs)
    • Publication Date:
      Date Created: 20250314 Date Completed: 20250513 Latest Revision: 20250513
    • Publication Date:
      20250513
    • Accession Number:
      PMC11905635
    • Accession Number:
      10.1186/s12885-025-13854-1
    • Accession Number:
      40082755